Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation
Recruiting · NCT07203482 · Observational (researchers observe without assigning treatment) · Lead sponsor: NYU Langone Health
View the official record on ClinicalTrials.gov →What this trial is about
Many reports of clinical outcomes following treatment of localized prostate cancer suffer from lack of prospective long-term data using objective and validated outcome instruments. The purpose of this research database is to prospectively collect data to assess treatment related complications, oncologic outcomes and urinary/sexual function, and identify predictors of complications, oncological control and functional outcomes after Hhigh-intensity focused ultrasound (HIFU) ablation of prostate cancer with the intent to guide further research and improve patient care. We will include subjects who will have a HIFU procedure performed from all Sub-Investigators included in the study.
Who can take part
Inclusion criteria
- Males, ages 40-95
- Evidence of focal prostate cancer confined to the prostate based on MRI imaging and prostate biopsy
- Patients with clinically localized prostate cancer (no evidence for or concern for metastatic spread of cancer outside of the prostate) that select focal HIFU prostate ablation as their treatment option will be offered inclusion into this prospective data collection research database.
- Patients who have early (Gleason 6 or 7), low grade cancer that is confined to the prostate.
- Willing and able to provide consent.
Exclusion criteria
- Patients that are not diagnosed with prostate cancer.
- Patients that are diagnosed with clinically localized prostate cancer, but select other tratment options as their desired treatment.
- Patients that are not willing or are not able to give consent.
Where it is running
2 locations listed across 1 US state.
- NYU Langone Health - Cobble Hill - Brooklyn, New York, United States
- NYU Langone Health - Tisch Hospital - New York, New York, United States